CMS' new ACCESS model, slated to begin on July 1, aims to shift traditional Medicare fee-for-service toward value-based care by tying payments to patient outcomes and encouraging tech-enabled, preventive care. Experts say it could benefit digitally mature, value-focused providers first, but its overall success will hinge on clear metrics, better data sharing and sustained participation.
CMS' new ACCESS model, slated to begin on July 1, aims to shift traditional Medicare fee-for-service toward value-based care by tying payments to patient outcomes and encouraging tech-enabled, preventive care. Experts say it could benefit digitally mature, value-focused providers first, but its overall success will hinge on clear metrics, better data sharing and sustained participation.
Claritev helps make healthcare clearer, smarter, and more affordable. With 40+ years of claims repricing expertise and powerful AI technology, we turn complex data into actionable insights. Our enterprise platform drives price transparency, optimizes networks, and reshapes benefit plan design—helping payers, providers, and employers deliver real value in healthcare.
Takeda said more than half of plaque psoriasis patients treated with zasocitinib achieved clear or almost clear skin in two Phase 3 studies. Regulatory submissions for the TYK2 inhibitor are planned for 2026 and clinical trials are ongoing in other indications.
With new therapies being approved, and many others in the pipeline, they raise a critical question: Is our healthcare system prepared to deliver them effectively and sustainably?
GE Healthcare showed off its imaging innovations at the Radiological Society of North America's annual conference this month in Chicago. Some of these included new MRI machines, CT scanning technology and radiology workstations.
Join MedCity News Associate Editor Katie Adams on her tour of GE's booth at the show!
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are working with the Trump administration to lower costs?
No comments